apartmentlkp.blogg.se - Doctors in training step 2 endocrine 8 answers

4.7.1.1 Experimentally-induced acute pain.4.5.3 Spinal cord injury (or spinal cord disease).4.5 Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury and disease.

4.4.2 To stimulate appetite and produce weight gain in cancer patients.

4.4.1 To stimulate appetite and produce weight gain in AIDS patients.

4.4 Wasting syndrome (cachexia, e.g., from tissue injury by infection or tumour) and loss of appetite (anorexia) in AIDS and cancer patients, and anorexia nervosa.

4.3 Chemotherapy-induced nausea and vomiting.

2.4 Tolerance, dependence, and withdrawal symptoms.

2.3 Pharmacokinetic-pharmacodynamic relationships.

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site.

Complete a Canada Vigilance Reporting Form and:.

Providing Health Canada with as much complete information as possible about the adverse reaction will help Health Canada with any follow-ups or actions that may be required.Īny suspected adverse reactions associated with the use of cannabis and cannabis products (dried, oils, fresh) for medical purposes should be reported to the Canada Vigilance Program by one of the following three ways: When reporting adverse reactions, please provide as much complete information as possible including the name of the licensed producer, the product brand name, the strain name, and the lot number of the product used in addition to all other information available for input in the adverse reaction reporting form.

Reporting adverse reactions associated with the use of cannabis and cannabis products is important in gathering much needed information about the potential harms of cannabis and cannabis products for medical purposes. The provision of this information should not be interpreted as an endorsement of the use of this product, or cannabis and cannabinoids generally, by Health Canada.ĭate of latest version: Spring 2018 Reporting Adverse Reactions to Cannabis (marihuana, marijuana) Products This document should not be construed as expressing conclusions or opinions from Health Canada about the appropriate use of cannabis (marihuana) or cannabinoids for medical purposes.Ĭannabis is not an approved therapeutic product, unless a specific cannabis product has been issued a drug identification number (DIN) and a notice of compliance (NOC). Despite the similarity of format, it is not a Drug Product Monograph, which is a document which would be required if the product were to receive a Notice of Compliance authorizing its sale in Canada. This document is not a systematic review or meta-analysis of the literature and has not rigorously evaluated the quality and weight of the available evidence nor has it graded the level of evidence.

It is not meant to be comprehensive and should be used as a complement to other reliable sources of information. This document is a summary of peer-reviewed literature and international reviews concerning potential therapeutic uses and harmful effects of cannabis and cannabinoids. This document has been prepared by the Cannabis Legalization and Regulation Branch at Health Canada to provide information on the use of cannabis (marihuana) and cannabinoids for medical purposes.